Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker.

Winfield JM, Wakefield JC, Dolling D, Hall M, Freeman S, Brenton JD, Lutchman-Singh K, Pace E, Priest AN, Quest RA, Taylor NJ, Gabra H, McKnight L, Collins DJ, Banerjee S, Hall E, deSouza NM.

Radiology. 2019 Oct 1:190545. doi: 10.1148/radiol.2019190545. [Epub ahead of print]

PMID:
31573402
2.

Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions.

Birtley JR, Alomary M, Zanini E, Antony J, Maben Z, Weaver GC, Von Arx C, Mura M, Marinho AT, Lu H, Morecroft EVN, Karali E, Chayen NE, Tate EW, Jurewicz M, Stern LJ, Recchi C, Gabra H.

Nat Commun. 2019 Jul 17;10(1):3134. doi: 10.1038/s41467-019-10966-8.

3.

Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification.

Anand P, Elsafa E, Privitera R, Naidoo K, Yiangou Y, Donatien P, Gabra H, Wasan H, Kenny L, Rahemtulla A, Misra P.

J Pain Res. 2019 Jul 3;12:2039-2052. doi: 10.2147/JPR.S213912. eCollection 2019.

4.

Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.

Hall M, Savvatis K, Nixon K, Kyrgiou M, Hariharan K, Padwick M, Owens O, Cunnea P, Campbell J, Farthing A, Stumpfle R, Vazquez I, Watson N, Krell J, Gabra H, Rustin G, Fotopoulou C.

Ann Surg Oncol. 2019 Sep;26(9):2943-2951. doi: 10.1245/s10434-019-07516-3. Epub 2019 Jun 26.

5.

Neuroblastoma of the Urinary Bladder in an Infant.

Mohamed A, Campbell-Hewson Q, Gabra HOS.

European J Pediatr Surg Rep. 2019 Jan;7(1):e32-e35. doi: 10.1055/s-0039-1692192. Epub 2019 Jun 17.

6.

Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population.

Alsaleh M, Barbera TA, Reeves HL, Cramp ME, Ryder S, Gabra H, Nash K, Shen YL, Holmes E, Williams R, Taylor-Robinson SD.

Hepat Med. 2019 May 3;11:47-67. doi: 10.2147/HMER.S193996. eCollection 2019.

7.

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA; BriTROC investigators.

Br J Cancer. 2019 Apr;120(8):868. doi: 10.1038/s41416-019-0433-6.

8.

A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer.

Lu H, Arshad M, Thornton A, Avesani G, Cunnea P, Curry E, Kanavati F, Liang J, Nixon K, Williams ST, Hassan MA, Bowtell DDL, Gabra H, Fotopoulou C, Rockall A, Aboagye EO.

Nat Commun. 2019 Feb 15;10(1):764. doi: 10.1038/s41467-019-08718-9.

9.

Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer.

Marinho AT, Lu H, Pereira SA, Monteiro E, Gabra H, Recchi C.

Front Pharmacol. 2019 Jan 28;9:1524. doi: 10.3389/fphar.2018.01524. eCollection 2018.

10.

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.

Blagden SP, Hamilton AL, Mileshkin L, Wong S, Michael A, Hall M, Goh JC, Lisyanskaya AS, DeSilvio M, Frangou E, Stronach EA, Gopalakrishna P, Meniawy TM, Gabra H.

Clin Cancer Res. 2019 Mar 1;25(5):1472-1478. doi: 10.1158/1078-0432.CCR-18-2277. Epub 2018 Dec 18.

PMID:
30563934
11.

The peripheral portacath provides safe and convenient venous access in pediatric and adolescent patients.

Herd F, Miller T, van Delft FW, Gabra HO.

J Pediatr Surg. 2019 Jul;54(7):1449-1452. doi: 10.1016/j.jpedsurg.2018.07.026. Epub 2018 Sep 12.

PMID:
30415954
12.

Risk factors for endometrial cancer: An umbrella review of the literature.

Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E, Martin-Hirsch P, Tsilidis KK, Kyrgiou M.

Int J Cancer. 2019 Oct 1;145(7):1719-1730. doi: 10.1002/ijc.31961. Epub 2019 Feb 20. Review.

PMID:
30387875
13.

Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients.

Cunnea P, Gorgy T, Petkos K, Gowers SAN, Lu H, Morera C, Wu W, Lawton P, Nixon K, Leong CL, Sorbi F, Domenici L, Paterson A, Curry E, Gabra H, Boutelle MG, Drakakis EM, Fotopoulou C.

Sci Rep. 2018 Oct 2;8(1):14695. doi: 10.1038/s41598-018-32720-8.

14.

Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.

Burmi RS, Maginn EN, Gabra H, Stronach EA, Wasan HS.

Cancer Biol Ther. 2019;20(1):21-30. doi: 10.1080/15384047.2018.1504718. Epub 2018 Sep 27.

15.

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.

Blagden SP, Rizzuto I, Suppiah P, O'Shea D, Patel M, Spiers L, Sukumaran A, Bharwani N, Rockall A, Gabra H, El-Bahrawy M, Wasan H, Leonard R, Habib N, Ghazaly E.

Br J Cancer. 2018 Oct;119(7):815-822. doi: 10.1038/s41416-018-0244-1. Epub 2018 Sep 12.

16.

Copy number signatures and mutational processes in ovarian carcinoma.

Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Paul J, Supernat A, Millan D, Hoyle A, Bryson G, Nourse C, Mincarelli L, Sanchez LN, Ylstra B, Jimenez-Linan M, Moore L, Hofmann O, Markowetz F, McNeish IA, Brenton JD.

Nat Genet. 2018 Sep;50(9):1262-1270. doi: 10.1038/s41588-018-0179-8. Epub 2018 Aug 13.

17.

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018 Jun 29.

18.

The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.

Antony J, Zanini E, Kelly Z, Tan TZ, Karali E, Alomary M, Jung Y, Nixon K, Cunnea P, Fotopoulou C, Paterson A, Roy-Nawathe S, Mills GB, Huang RY, Thiery JP, Gabra H, Recchi C.

EMBO Rep. 2018 Aug;19(8). pii: e45670. doi: 10.15252/embr.201745670. Epub 2018 Jun 15.

19.

Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.

Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R.

Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.

20.

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S.

Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22.

21.

Obesity and gynaecological and obstetric conditions: umbrella review of the literature.

Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Mitra A, Terzidou V, Bennett P, Martin-Hirsch P, Tsilidis KK, Kyrgiou M.

BMJ. 2017 Oct 26;359:j4511. doi: 10.1136/bmj.j4511. Review.

22.

A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.

Kreuzinger C, Geroldinger A, Smeets D, Braicu EI, Sehouli J, Koller J, Wolf A, Darb-Esfahani S, Joehrens K, Vergote I, Vanderstichele A, Boeckx B, Lambrechts D, Gabra H, Wisman GBA, Trillsch F, Heinze G, Horvat R, Polterauer S, Berns E, Theillet C, Cacsire Castillo-Tong D.

Clin Cancer Res. 2017 Dec 15;23(24):7621-7632. doi: 10.1158/1078-0432.CCR-17-1159. Epub 2017 Oct 2.

23.

Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.

Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM.

J Surg Oncol. 2018 Feb;117(2):236-244. doi: 10.1002/jso.24801. Epub 2017 Aug 8.

24.

The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.

Zanini E, Louis LS, Antony J, Karali E, Okon IS, McKie AB, Vaughan S, El-Bahrawy M, Stebbing J, Recchi C, Gabra H.

Mol Cancer Ther. 2017 Oct;16(10):2246-2256. doi: 10.1158/1535-7163.MCT-17-0081. Epub 2017 Aug 3.

25.

WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.

Janczar S, Nautiyal J, Xiao Y, Curry E, Sun M, Zanini E, Paige AJ, Gabra H.

Cell Death Dis. 2017 Jul 27;8(7):e2955. doi: 10.1038/cddis.2017.346.

26.

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.

27.

British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.

Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, Kehoe S, Ledermann J, Morrison J, Naik R, Rolland P, Sundar S.

Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:123-139. doi: 10.1016/j.ejogrb.2017.04.016. Epub 2017 Apr 18. No abstract available.

28.

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Goranova T, Ennis D, Piskorz AM, Macintyre G, Lewsley LA, Stobo J, Wilson C, Kay D, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gabra H, Freeman S, Moore L, Jimenez-Linan M, Paul J, Brenton JD, McNeish IA.

Br J Cancer. 2017 May 9;116(10):1294-1301. doi: 10.1038/bjc.2017.86. Epub 2017 Mar 30. Erratum in: Br J Cancer. 2019 Apr;120(8):868.

29.

Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.

Phelps DL, Borley JV, Flower KJ, Dina R, Darb-Esfahani S, Braicu I, Sehouli J, Fotopoulou C, Wilhelm-Benartzi CS, Gabra H, Yazbek J, Chatterjee J, Ip J, Khan H, Likos-Corbett MT, Brown R, Ghaem-Maghami S.

Br J Cancer. 2017 May 9;116(10):1287-1293. doi: 10.1038/bjc.2017.83. Epub 2017 Mar 28.

30.

Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival-A Case Series.

Domenici L, Nixon K, Sorbi F, Kyrgiou M, Yazbek J, Hall M, Campbell J, Gibbons N, Park WE, Gabra H, Fotopoulou C.

Int J Gynecol Cancer. 2017 May;27(4):759-767. doi: 10.1097/IGC.0000000000000936.

31.

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.

Diamond JR, Goff B, Forster MD, Bendell JC, Britten CD, Gordon MS, Gabra H, Waterhouse DM, Poole M, Ross Camidge D, Hamilton E, Moore KM.

Invest New Drugs. 2017 Oct;35(5):627-633. doi: 10.1007/s10637-017-0444-1. Epub 2017 Mar 10.

32.

Adiposity and cancer at major anatomical sites: umbrella review of the literature.

Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Martin-Hirsch P, Tsilidis KK.

BMJ. 2017 Feb 28;356:j477. doi: 10.1136/bmj.j477. Review.

33.

Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.

Fotopoulou C, Sehouli J, Aletti G, Harter P, Mahner S, Querleu D, Chiva L, Gabra H, Colombo N, du Bois A.

J Clin Oncol. 2017 Feb 20;35(6):587-590. doi: 10.1200/JCO.2016.71.0723. Epub 2017 Jan 9. No abstract available.

34.

TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.

Amoroso MR, Matassa DS, Agliarulo I, Avolio R, Lu H, Sisinni L, Lettini G, Gabra H, Landriscina M, Esposito F.

Cell Death Dis. 2016 Dec 15;7(12):e2522. doi: 10.1038/cddis.2016.400.

35.

Endocrine therapy in epithelial ovarian cancer.

Langdon SP, Gourley C, Gabra H, Stanley B.

Expert Rev Anticancer Ther. 2017 Feb;17(2):109-117. doi: 10.1080/14737140.2017.1272414. Epub 2016 Dec 24. Review.

36.

Gastrointestinal complications associated with the surgical treatment of heart disease in children.

Ferguson LP, Gandiya T, Kaselas C, Sheth J, Hasan A, Gabra HO.

J Pediatr Surg. 2017 Mar;52(3):414-419. doi: 10.1016/j.jpedsurg.2016.10.052. Epub 2016 Nov 14.

PMID:
27916446
37.

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.

Alifrangis C, Thornton A, Fotopoulou C, Krell J, Gabra H.

Gynecol Oncol Rep. 2016 Nov 6;18:42-44. eCollection 2016 Nov.

38.

Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.

Nasser S, Lazaridis A, Evangelou M, Jones B, Nixon K, Kyrgiou M, Gabra H, Rockall A, Fotopoulou C.

Gynecol Oncol. 2016 Nov;143(2):264-269. doi: 10.1016/j.ygyno.2016.08.322. Epub 2016 Aug 29.

PMID:
27586894
39.

The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.

Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, Gabra H, Thiery JP, Huang RY.

Sci Signal. 2016 Oct 4;9(448):ra97.

40.

Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.

Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, Flower K, Wilhelm-Benartzi C, Hergovich A, Cunnea P, Gabra H, Braicu EI, Sehouli J, Darb-Esfahani S, Vanderstichele A, Vergote I, Kreuzinger C, Castillo-Tong DC, Wisman GBA, Berns EM, Siddiqui N, Paul J, Brown R.

Clin Cancer Res. 2017 May 1;23(9):2213-2222. doi: 10.1158/1078-0432.CCR-16-1754. Epub 2016 Sep 23.

41.

Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.

Wu W, Wang Q, Yin F, Yang Z, Zhang W, Gabra H, Li L.

Int J Oncol. 2016 Oct;49(4):1651-65. doi: 10.3892/ijo.2016.3652. Epub 2016 Aug 10.

42.

Integrative Analysis of Subcellular Quantitative Proteomics Studies Reveals Functional Cytoskeleton Membrane-Lipid Raft Interactions in Cancer.

Shah AD, Inder KL, Shah AK, Cristino AS, McKie AB, Gabra H, Davis MJ, Hill MM.

J Proteome Res. 2016 Oct 7;15(10):3451-3462. Epub 2016 Sep 2.

43.

Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.

Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, Faicchia D, Maddalena F, Simeon V, Agliarulo I, Zanini E, Mazzoccoli C, Recchi C, Stronach E, Marone G, Gabra H, Matarese G, Landriscina M, Esposito F.

Cell Death Differ. 2016 Sep 1;23(9):1542-54. doi: 10.1038/cdd.2016.39. Epub 2016 May 20.

44.

Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities.

Fotopoulou C, Jones BP, Savvatis K, Campbell J, Kyrgiou M, Farthing A, Brett S, Roux R, Hall M, Rustin G, Gabra H, Jiao L, Stümpfle R.

Arch Gynecol Obstet. 2016 Sep;294(3):607-14. doi: 10.1007/s00404-016-4080-3. Epub 2016 Apr 4.

45.

Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy.

Kyriakides M, Rama N, Sidhu J, Gabra H, Keun HC, El-Bahrawy M.

Oncotarget. 2016 Feb 9;7(6):7216-26. doi: 10.18632/oncotarget.6891.

46.

Introduction to managing patients with recurrent ovarian cancer.

Gabra H.

EJC Suppl. 2014 Dec;12(2):2-6. doi: 10.1016/S1359-6349(15)70003-0. Epub 2015 Jan 13.

47.

Foreword.

Gabra H.

EJC Suppl. 2014 Dec;12(2):1. doi: 10.1016/S1359-6349(15)70002-9. Epub 2015 Jan 13. No abstract available.

48.

A method for voltage measurements of cancerous vs non-cancerous omentum.

Wu W, Vitharana K, Gorgy T, Paterson A, Cunnea P, Gabra H, Fotopoulou C, Boutelle MG, Drakakis EM.

Conf Proc IEEE Eng Med Biol Soc. 2015;2015:7514-7. doi: 10.1109/EMBC.2015.7320130.

PMID:
26738030
49.

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15716. Epub 2015 Oct 21. No abstract available.

PMID:
26503049
50.

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.

Cheraghchi-Bashi A, Parker CA, Curry E, Salazar JF, Gungor H, Saleem A, Cunnea P, Rama N, Salinas C, Mills GB, Morris SR, Kumar R, Gabra H, Stronach EA.

Oncotarget. 2015 Dec 8;6(39):41736-49. doi: 10.18632/oncotarget.6153.

Supplemental Content

Support Center